Details

Autor(en) / Beteiligte

• Margaritopoulos, George A
• Trachalaki, Athina
• Wells, Athol U
• Vasarmidi, Eirini
• Bibaki, Eleni
• Papastratigakis, George
• Detorakis, Stathis
• Tzanakis, Nikos
• Antoniou, Katerina M

Titel

Pirfenidone improves survival in IPF: results from a real-life study

Ist Teil von

• BMC pulmonary medicine, 2018-11, Vol.18 (1), p.177-177, Article 177

Ort / Verlag

England: BioMed Central Ltd

Erscheinungsjahr

2018

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Pirfenidone is an antifibrotic compound approved for the treatment of idiopathic pulmonary fibrosis (IPF). We present our real-world experience in terms of Pirfenidone's effect on mortality and adverse events profile outside the restrictions of a clinical trial. This is a retrospective observational intention to treat study of 82 consecutive IPF patients (UHH cohort). We observed a high 3-years survival rate of 73% without excluding patients who discontinued treatment for different reasons. The survival was compared to the survival of an IPF cohort from a tertiary referral center (RBH cohort). After exclusion of severe cases (DLco< 30%), in unadjusted analysis, the survival in the UHH cohort was better than in the RBH cohort (HR:0.32, 95% CI: 0.19-0.53, p < 0.0001). After adjustment for age, gender and FVC, the survival remained higher in the UHH cohort (HR:0.28, 95% CI: 0.16-0.48, p < 0.0001). We observed a similar safety profile compared to previously published data and a lower rate of drug discontinuation due to photosensitivity reactions. Pirfenidone provides a survival benefit in a real-life IPF cohort compared to previously used medications. Counselling patients and proactively managing possible adverse effects can reduce the necessity to discontinue pirfenidone.